OICR-9429
目录号 : GC16397
OICR-9429是一种有效的高亲和力的WD repeat domain 5（WDR5）抑制剂，与WDR5结合的Kd值为93±28nM。
Cas No.:1801787-56-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
OICR-9429 is an effective and highly potent inhibitor of the WD repeat domain 5 (WDR5) with a Kd value of 93 ± 28nM [1]. WDR5 is a common scaffold protein that typically forms a nucleosome-modifying protein complex with histones. OICR-9429 binds competitively to the central peptide binding pocket of WDR5, blocking the interaction between WDR5 and the mixed-lineage leukemia (MLL) protein [2-3]. OICR-9429 can be used in the research of various cancers such as non-MLL rearrangement leukemia, colon cancer, pancreatic cancer, prostate cancer, and bladder cancer [4].
In vitro, OICR-9429 (0-400μM; 48h) inhibited the cell proliferation and metastasis of bladder cancer cell lines (T24, UM-UC-3, and TCCSUP) in a dose-dependent manner, promoted the level of cell apoptosis, and reduced the H3K4me3 level in the cells [5]. OICR-9429 (75 and 100μM; 48h) treatment significantly reduced the viability and colony formation ability of PCa cells in a dose-dependent manner, and induced G0/G1 phase arrest [6].
In vivo, OICR-9429 (30 and 60mg/kg/day; every 2 days for 16 days; i.p.) treatment significantly inhibited the tumor growth of bladder cancer cell (BCa) xenograft mice, enhanced chemosensitivity, and reduced the toxicity of cisplatin in BCa [5]. OICR-9429 (1mg/kg/day; i.p.) treatment reduced the peritoneal cell density and the thickness of the interstitial dense zone in mice with peritoneal fibrosis induced by methylglyoxal (MGO), decreased the number of H3K4me3 positive cells, and alleviated the peritoneal fibrosis and inflammation in mice [7].
References:
[1] Grebien F, Vedadi M, Getlik M, et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol. 2015;11(8):571-578.
[2] Migliori, V., Mapelli, M., and Guccione, E. On WD40 proteins: Propelling our knowledge of transcriptional control Epigenetics 7(8), 815-822 (2012).
[3] Guccione, E., Bassi, C., Casadio, F., et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature 449, 933-937 (2007).
[4] Gurung R, Om D, Pun R, et al. Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders. Cancers 2023, 15, 3910[EB/OL].(2023)
[5] Zhang J, Zhou Q, Xie K, et al. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer. J Exp Clin Cancer Res. 2021;40(1):203. Published 2021 Jun 21.
[6] Zhou Q, Chen X, He H, et al. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer[J]. Theranostics, 2021, 11(10): 4809.
[7] Hara D, Sasaki K, Doi S, et al. Targeting MLL1/WDR5‐Mediated Epigenetic Regulation Mitigates Peritoneal Fibrosis by Reducing p16INK4a[J]. The FASEB Journal, 2025, 39(8): e70543.
OICR-9429是一种有效的高亲和力的WD repeat domain 5（WDR5）抑制剂，与WDR5结合的Kd值为93±28nM [1]。WDR5是一种常见的支架蛋白，通常与组蛋白形成核小体修饰蛋白复合物。OICR-9429通过与WDR5的中心肽结合口袋结合，竞争性地阻断WDR5与混合谱系白血病（MLL）蛋白的相互作用 [2-3]。OICR-9429可用于非MLL重排白血病、结肠癌、胰腺癌、前列腺癌、膀胱癌等多种癌症的研究 [4]。
在体外，OICR-9429（0-400μM; 48h）以剂量依赖性方式抑制了膀胱癌细胞系（T24、UM-UC-3和TCCSUP）的细胞增殖和转移，促进了细胞凋亡水平并降低了细胞中的H3K4me3水平 [5]。OICR-9429（75和100μM; 48h）处理以剂量依赖性方式显著降低了PCa细胞的活力和集落形成能力，并诱导G0/G1相停滞 [6]。
在体内，OICR-9429（30和60mg/kg/day; every 2 days for 16 days; i.p.）治疗显著抑制了膀胱癌细胞（BCa）异种移植小鼠的肿瘤生长，增强化学敏感性并降低顺铂在BCa中的毒性 [5]。OICR-9429（1mg/kg/day; i.p.）治疗降低了甲基乙二醛（MGO）诱导的腹膜纤维化小鼠的腹膜细胞密度和间皮下致密区厚度，减少了H3K4me3阳性细胞的数量，减轻了小鼠的腹膜纤维化和炎症 [7]。
| Cell experiment [1]: | |
Cell lines | T24, UM-UC-3, and TCCSUP cells |
Preparation Method | Cells were grown in a 37 °C, 5% CO2 cell incubator with humidified atmosphere. Then the cells were treated with 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 200, 300, and 400μM OICR-9429 for 48h. Cell viability was detected using the MTT assay. |
Reaction Conditions | 0-400μM; 48h |
Applications | OICR-9429 inhibited the cell proliferation of bladder cancer cell lines in a dose-dependent manner. |
| Animal experiment [1]: | |
Animal models | BALB/c nude mice |
Preparation Method | For the xenograft mouse model, a total of 3 × 106 UM-UC-3 cells were injected subcutaneously into the right side of the dorsum, and there were 6 nude mice in every treatment group. Five days after injection, tumour-bearing mice were randomly assigned into four groups that received control solvent, OICR-9429 (60mg/kg), cisplatin (4mg/kg), or a combination of small dose OICR-9429 (30mg/kg) and cisplatin (2.5mg/kg). OICR-9429 was diluted in a combination solution of 5% DMSO + 40% PEG300 + 2% Tween 80 + 53% sterilized water, and cisplatin was diluted in sterilized PBS solution. OICR-9429 and chemotherapy were given every 2 days by intraperitoneal injection. After 16 days of treatment, the mice were euthanized, and tumours were surgically dissected. The tumour and organ specimens were fixed in 4% paraformaldehyde, embedded in paraffin, and then stained with H&E staining. |
Dosage form | 30 and 60mg/kg/day; every 2 days for 16 days; i.p. |
Applications | OICR-9429 treatment significantly inhibited the tumor growth of bladder cancer cell xenograft mice, enhanced chemosensitivity and reduced the toxicity of cisplatin. |
References: | |
| Cas No. | 1801787-56-3 | SDF | |
| 化学名 | N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide | ||
| Canonical SMILES | O=C(C(C(C(F)(F)F)=C1)=CNC1=O)NC2=CC(C3=CC=CC(CN4CCOCC4)=C3)=CC=C2N5CCN(C)CC5 | ||
| 分子式 | C29H32F3N5O3 | 分子量 | 555.59 |
| 溶解度 | DMSO: 0.5 mg/ml (with gentle warming),Methanol: 0.5 mg/ml (with gentle warming) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7999 mL | 8.9994 mL | 17.9989 mL |
| 5 mM | 360 μL | 1.7999 mL | 3.5998 mL |
| 10 mM | 180 μL | 899.9 μL | 1.7999 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet